Skip to main content
SpringerLink
Log in

Choice of Long-Acting Insulin Therapy for Type 2 Diabetes

How Can Treatment for Older People be Optimized?

  • Editorial
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Evans A, Krentz AJ. Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus. Drug Safety 1999; 21: 7–22

    Article  PubMed  CAS  Google Scholar 

  2. Dominguez LJ, Paolisso G, Barbagallo M. Glucose control in the older patient: from intensive, to effective and safe. Aging Clin Exp Res 2010; 22: 274–80

    PubMed  Google Scholar 

  3. Sinclair AJ, Conroy SP, Bayer AJ. Impact of diabetes on physical function in older people. Diabetes Care 2008; 31: 233–5

    Article  PubMed  Google Scholar 

  4. Chen LK, Chen YM, Lin MH, et al. Care of elderly patients with diabetes mellitus: a focus on frailty. Ageing Res Rev 2010; 9Suppl. 1: S18–22

    Article  PubMed  Google Scholar 

  5. Paolisso G. Pathophysiology of diabetes in elderly people. Acta Biomed 2010; 1Suppl. 1: 47–53

    Google Scholar 

  6. DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003; 26: 61–9

    Article  Google Scholar 

  7. Currie CJ, Gale EA, Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with type 1 and type 2 diabetes in the United Kingdom from 1997 to 2007. Diabet Med 2010; 27: 938–48

    Article  PubMed  CAS  Google Scholar 

  8. Gale EA. Diabetes in the UK: time for a reality check? Diabet Med 2010; 27: 973–6

    Article  PubMed  CAS  Google Scholar 

  9. Cohen D, Carter P. How small changes led to big profits for insulin manufacturers. BMJ 2010; 341: c7139

    Article  PubMed  Google Scholar 

  10. Type 2 diabetes: newer agents (partial update of CG66). NICE [online]. Available from URL: http://www.nice.org.uk/CG87 Accessed 2011 May 29]

  11. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174–83

    Article  PubMed  CAS  Google Scholar 

  12. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080–6

    Article  PubMed  CAS  Google Scholar 

  13. Rosenstock J, Fonseca V, McGill JB, et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 2009; 52: 1778–88

    Article  PubMed  CAS  Google Scholar 

  14. Heller SR. Hypoglycaemia in type 2 diabetes. Diabetes Res Clin Pract 2008; 82Suppl. 2: S108–11

    Article  PubMed  CAS  Google Scholar 

  15. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736–47

    Article  PubMed  CAS  Google Scholar 

  16. Unnikrishnan AG, Tibaldi J, Hadley-Brown M, et al. Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement. Int J Clin Pract 2009; 63: 1571–7

    Article  PubMed  CAS  Google Scholar 

  17. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007 Apr 18; (2): CD005613

    Google Scholar 

  18. Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab 2009; 11: 53–9

    Article  PubMed  CAS  Google Scholar 

  19. Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008; 149: 549–59

    PubMed  Google Scholar 

  20. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59

    Article  PubMed  CAS  Google Scholar 

  21. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–39

    Article  PubMed  CAS  Google Scholar 

  22. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1699–708

    Article  PubMed  CAS  Google Scholar 

  23. Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009; 52:1971–3

    Article  PubMed  CAS  Google Scholar 

  24. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17–30

    Article  PubMed  CAS  Google Scholar 

  25. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine Practice 2009; 15: 540–59

    PubMed  Google Scholar 

  26. Sinclair AJ. A report of the European Diabetes Working Party for Older People (EDWPOP): diabetes and metabolism. Amsterdam: Elsevier. In press

  27. Marouf E, Sinclair AJ. Use of short-acting insulin aspart in managing older people with diabetes. Clin Interv Aging 2009; 4: 187–90

    PubMed  CAS  Google Scholar 

  28. Fonseca V, Davidson J, Home P, et al. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Curr Med Res Opin 2010; 26: 1621–8

    Article  PubMed  CAS  Google Scholar 

  29. Werner H, Weinstein D, Yehezkel E, et al. Controversies in the use of insulin analogues. Expert Opin Biol Ther 2011; 11: 199–209

    Article  PubMed  CAS  Google Scholar 

  30. Prescribing for diabetes in England 2005/06 to 2010/11. NHS, 2011 Aug 24 [online]. Available from URL: http://www.ic.nhs.uk/pubs/prescribingfordiabetes05-11 [Accessed 2011 Aug 26]

  31. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009; 180: 400–7

    Article  PubMed  Google Scholar 

  32. Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother 2009; 7: 324–42

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have received professional consultancy fees, grant funding and/or fees for consultancies and lectures from Bioton S.A., Eli Lilly, NovoNordisk, Pfizer and Sanofi-Aventis. No financial support was received for this article, which reflects the authors’ personal opinions.

Author information

Authors and Affiliations

  1. Institute of Diabetes for Older People, Bedfordshire and Hertfordshire Postgraduate Medical School, University of Bedfordshire, Putteridge Bury Campus, Hitchin Road, Luton, LU2 8LE, UK

    Andrew J. Krentz & Alan J. Sinclair

Authors
  1. Andrew J. Krentz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan J. Sinclair
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew J. Krentz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krentz, A.J., Sinclair, A.J. Choice of Long-Acting Insulin Therapy for Type 2 Diabetes. Drugs Aging 28, 935–941 (2011). https://doi.org/10.2165/11597820-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11597820-000000000-00000

Search

Navigation